Immuno-oncology models

Advancing immuno-oncology research with in vivo models

Immunotherapy has revolutionised cancer treatment by harnessing the patient's immune system to target and eliminate cancer cells. Our syngeneic mouse models are crucial for investigating immune response mechanisms and assessing the effectiveness of immunotherapeutic agents. We support your immuno-oncology projects by profiling drug candidates in the most relevant models, integrating efficacy endpoints with ex vivo analyses to study the effects on immune cells.

An artistic depiction of an antibody binding to a cell-surface protein

In vivo models for immuno-oncology research

In addition to general oncology study types and readouts, we offer a well-characterised portfolio of cell line-derived syngeneic immuno-oncology (IO) models, tailored to meet your research needs. Our models include comprehensive evaluation of major immune cell subsets, correlated with tumour progression. We utilise cell line-derived xenograft (CDX) syngeneic tumour models to study cancer therapies in the presence of a functional immune system. Additionally, we provide hPBMC/HSC/T-cell humanised models.

Anti-tumor efficacy studies (including tolerability and exposure studies)
Syngeneic CDX derived models
Humanised mouse models (PBMCs, HSCs, T-cells)
Pharmacokinetic (PK) and pharmacodynamic (PD) assessments
In vivo imaging (bioluminescence, fluorescence)
Cytokine and immuno-profiling employing spectral flow cytometry (>28 parameters)
Single-cell RNA sequencing
Profiling of tumor-infiltrating lymphocytes and immuno-modulation effects
Single and multi-color fluorescent and chromogenic staining
In situ hybridization (RNAscope).

Related topics & resources

Multicolor immunofluorescence (mIF) for immune cell infiltration

In vivo biomarker services

Discover the power of in vivo biomarker analysis to bridge the gap between preclinical research and clinical success.

Learn more

Sepcific detection of nucleid labeled nucleic acids in cortical tubules

In vivo pharmacology models

Find out how we can support your drug discovery journey with our in vivo pharmacology models.

Learn more

Antibodies with cytotoxic drugs to selectively deliver treatment to disease sites

Antibody drug conjugates

Our scientists can collaborate with you to advance cancer treatment with antibody-drug-conjugates (ADCs).

Learn more